Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q1 2020 · 10-Q
Revenue$94.98M$94.98M+11.1% vs Q1 2019 Net Income$21.52M$21.52M+17.3% vs Q1 2019 EPS Diluted$0.40$0.40+17.6% vs Q1 2019 Operating Income$29,012,000+14.1% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
Free Cash Flowderived$6,379,000−80.5% Margins · derivedOperating margin30.5%+0.8 pt vs Q1 2019
Net margin22.7%+1.2 pt vs Q1 2019
ended Mar 31, 2020 · filed May 15, 2020 · 45 d after period end